Proteome Regulatory News (PRM)

Proteome Sciences plc

Protein Biomarker Collaboration with Thermo Fisher Scientific

23 September 2010, London, UK - Proteome Sciences (AIM:PRM) is pleased to announce a new additional collaboration with Thermo Fisher Scientific Inc. to deliver innovative products in protein biomarker research and to further develop quantitative proteomic workflows for biomarker discovery and validation. For its role in the collaboration, Proteome Sciences will combine state-of-the-art Thermo Scientific mass spectrometry technology with its integrated PS Biomarker Services workflow incorporating tandem mass tag (TMT®) reagents.

This new collaboration means that Proteome Sciences will now be working with its existing Reagents in the practical application of biomarker technology, opening up new and significant revenue opportunities to both Proteome Sciences and Thermo Fisher.

Full details of the Press Release issued by Thermo Fisher Scientific can be found at www.thermo.com/news and on www.proteomics.com/pages/news/1/.

Commenting on the collaboration from the HUPO Conference, Sydney, Dr. Ian Pike, Proteome's Chief Operating Officer stated:

"The Thermo Scientific Orbitrap LTQ Velos mass spectrometer, with its unique combination of HCD and ETD fragmentation, will allow us to extend the scope of proteomic services we offer to customers and extends the scope of future revenues. When using the TSQ™ Vantage in combination with our proprietary TMT tandem mass tag technology for assay development, we can offer the most integrated biomarker discovery, qualification and assay validation workflows in the industry.

"We have already successfully used TMT technology to develop mass spec assays for blood biomarkers in Alzheimer's disease and are expanding our coverage for other proprietary biomarkers in cancer and brain damage.

"This considerably extends, strengthens and enhances the existing arrangements and license that we have with Thermo Fisher. Access to these resources and our protein biomarker services can be outsourced from our PS Biomarker Services Division in Frankfurt where Proteome has recently installed Thermo Scientific LTQ Orbitrap Velos and TSQ Vantage mass spectrometer systems."

- Ends -

For further information please contact:

Proteome Sciences plc

www.proteomics.com Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com 

James Malthouse, Finance Director james.malthouse@proteomics.com 

Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com 

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: +44 (0)20 3205 7500

Public Relations

IKON Associates Redleaf Communications Limited

Adrian Shaw Anna Dunkin/Lucy Salaman

Tel: +44 (0)1483 271291 Tel: +44 (0)20 7566 6700

Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com 

Email: adrian@ikonassociates.com

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and uses high sensitivity proprietary technologies for protein biomarker discovery, validation and assay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications. These biomarkers are available for outlicensing. The first blood test for lung cancer using Proteome Sciences' biomarkers was launched in the USA in 2009 and received Medicare reimbursement in 2010. Its PS Biomarker Services provides ISO 9001: 2008 accredited facilities in Frankfurt, Germany, using proprietary isobaric and isotopic Tandem Mass Tags® (TMT®) to discover protein biomarkers, and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in validation studies. Assays for validated biomarkers can be transferred for immunoassay development. Proteome Sciences, based in Cobham, UK, has facilities in London and Frankfurt and delivers outsourced proteomics services and proprietary biomarkers to pharmaceutical, biotechnology and diagnostics companies. Visit http://www.proteomics.com.